Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.14 USD | -2.16% | -9.56% | +0.12% |
Jun. 01 | Transcript : Iovance Biotherapeutics, Inc. - Special Call | |
May. 13 | Truist Securities Trims Iovance Biotherapeutics' Price Target to $25 From $26, Buy Rating Maintained | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- Sales forecast by analysts have been recently revised upwards.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.12% | 2.33B | D+ | ||
-39.62% | 8.41B | A- | ||
+7.28% | 3.82B | C | ||
-21.06% | 2.02B | - | B- | |
-22.17% | 1.67B | C+ | ||
+29.16% | 1.14B | B- | ||
+28.50% | 760M | C- | ||
-9.39% | 697M | C+ | ||
-20.20% | 566M | C- | ||
-1.29% | 290M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IOVA Stock
- Ratings Iovance Biotherapeutics, Inc.